cjc 1295 vs hgh: Frequently asked questions

Water retention with CJC-1295 is typically mild and resolves within 2–3 weeks as aldosterone regulation normalises. With HGH, it's more pronounced because sustained GH elevation increases sodium retention via direct renal effects. This is the mechanism behind carpal tunnel syndrome in long-term HGH users. Reduce sodium intake to under 2,000 mg daily, increase potassium-rich foods (spinach, avocado), and consider a mild natural diuretic like dandelion root extract. If symptoms persist beyond 4 weeks on HGH, dose reduction is usually necessary.

Choose recombinant HGH. The sustained plasma elevation rhGH produces creates predictable IGF-1 levels across the 24-hour cycle, simplifying sample timing and reducing inter-day variance. CJC-1295's pulsatile pattern means IGF-1 values fluctuate significantly depending on whether sampling occurs during or between GH pulses. A confounding variable unless the research specifically examines pulsatility itself.

CJC-1295 maintains pituitary function across extended protocols. RhGH suppresses endogenous GH secretion through negative feedback. Clinical data shows pituitary GH output remains blunted for weeks to months after rhGH cessation. If the study design requires washout periods or post-treatment endogenous GH measurement, CJC-1295's preservation of hypothalamic-pituitary feedback makes it the only viable option.

Transition gradually. If you stop exogenous HGH abruptly after 12+ weeks, your pituitary may take 4–8 weeks to restore baseline GH secretion. During that window, IGF-1 drops and you risk losing lean mass. Taper HGH dose by 25% every two weeks while introducing CJC-1295 at standard dosing. By week 6–8, your endogenous pulses should recover enough to maintain IGF-1 in the physiological range (200–300 ng/mL for most adults). Monitor serum IGF-1 every 4 weeks during the transition. If it drops below 150 ng/mL, slow the taper.

Use a CJC-1295 protocol combined with a GHRP like ipamorelin or GHRP-2. The GHRH analog (CJC-1295) stimulates GH release; the GHRP amplifies pulse amplitude by blocking somatostatin (the hormone that inhibits GH secretion). This combination increases IGF-1 by 30–50% without suppressing your baseline pulsatility. Your pituitary continues functioning normally. Dose CJC-1295 at 1–2 mg per week and pair it with 100–200 mcg of a GHRP before bed to maximise overnight GH pulses. Research peptide suppliers like Real Peptides offer both compounds synthesised to research-grade purity standards.

CJC-1295 is the safer choice. Research from the University of Virginia Endocrinology Department found that pulsatile GH exposure preserves insulin sensitivity better than continuous elevation. Sustained GH antagonizes insulin signaling at the glucose transporter level, worsening hyperglycemia in insulin-resistant models. RhGH at high doses can precipitate glucose intolerance; CJC-1295's pulsatile effect minimizes this risk.